Can your DNA predict how you respond to a diabetes drug?
NCT ID NCT07739537
First seen Jul 31, 2026 · Last updated Sep 01, 2026 · Updated 2 times
Summary
This study investigates how different genetic pathways affect the body's response to food and to a short course of orforglipron, an oral GLP-1 drug used for weight management and blood sugar control. Researchers will enroll about 100 adults, with or without type 2 diabetes, who are not on more than two oral diabetes medications. Participants will undergo detailed metabolic tests, including meal challenges, to measure glucose and insulin responses, aiming to uncover subtypes of diabetes and personalize treatment approaches.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- orforglipron
- What this could lead to
- If successful, this could help tailor type 2 diabetes treatments based on a person's genetic profile, making therapies more effective and personalized.
- What could go wrong
- This is a small, early-stage study focused on understanding biology, not proving a treatment works. Results may not apply to everyone, and orforglipron can cause side effects like nausea or digestive issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Oct 2026
An estimate. Start dates often move.
- Expected to finish
-
Sep 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 79 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adult male or non-pregnant female volunteers (Age 18-79) * Not currently taking more than two home oral antidiabetic agents, with or without a diagnosis of type 2 diabetes * Able and willing to stop home oral antidiabetic medications for 5 days prior to the start of the study, with approval from healthcare providers * Able and willing to give informed consent Exclusion Criteria: * Known contraindication for orforglipron (e.g., Personal or family history of medullary thyroid cancer (MTC) or multiple endocrine neoplasia type 2 (MEN 2), allergies to any component) * Personal history of pancreatitis, gallbladder disease, intestinal malabsorption, severe gastroparesis, gastric outlet obstruction, or other clinically significant gastrointestinal motility disorder * History of liver disease or aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>3 x upper limit of normal * Estimated glomerular filtration rate (eGFR) \< 45 mg/min/1.73m2 per the Modification of Diet in Renal Disease equation * Active gallbladder disease or cholecystectomy within the past 6 months * Current use of a strong CYP3A4 inducer (e.g., rifampin, carbamazepine, phenytoin, phenobarbital, rifabutin, or St. John's wort) or ritonavir, cobicistat, cyclosporine, or another strong CYP3A4 inhibitor that also inhibits OATP1B * Current simvastatin dose \>20 mg daily * Measured most recent HbA1c level greater than 7.5% in the last 6 months * Average glucose by fingerstick or continuous glucose monitor exceeding 180 mg/dL in the last 3 months * Current uses of any oral or injectable GLP-1 receptor agonists, insulin, or the use of two or more antidiabetic agents * Currently taking or planning to start other medication known to affect glycemic parameters, such as glucocorticoids, growth hormone, or fluoroquinolones during the study * Planned to change any prescribed medication during the study * Planned surgeries or procedures requiring general anesthesia during or within 10 days after completing the study * Participating in any other interventional study simultaneously * Dietary restrictions that prevent the consumption of the standardized liquid mixed meal * Pregnant, nursing, or postpartum in the last 6 months * Current suicidal ideation or suicide attempt within the past 5 years * Psychiatric illness, substance use disorder, or eating disorder that, in the opinion of the investigator, would compromise participant safety or study compliance
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Diabete type 2 are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A special MRI peers into the chemistry of hearts and brains in diabetes
- Can pole walking boost heart fitness in diabetic patients?
- Can transplanted cells restore insulin production in type 2 diabetes?
- Could a common diabetes drug weaken or protect aging muscles?
- Gamifying exercise: could a phone app outperform traditional programs for obesity and diabetes?
- Antioxidant-rich diets may fight inflammation in type 2 diabetes — a study investigates